Article Text

Download PDFPDF

168 A novel prostate-restricted tumor-associated antigen: a potential therapeutic target
  1. Zoila (Areli) Lopez Bujanda1,
  2. Aleksandar Obradovic1,
  3. Thomas Nirschl2,
  4. Timothy O’Donnell3,
  5. Uri Laserson3,
  6. Rodney Macedo-Gonzales1,
  7. Ran Reshef1,
  8. Tiezheng Yuan2,
  9. Mithil Soni1,
  10. Emmanuel Antonarakis4,
  11. Benjamin Larman2,
  12. Pawel Muranski1,
  13. Charles Drake1 and
  14. Zoila (Areli) Lopez Bujanda1
  1. 1Columbia University Irving Medical Center, New York, NY, USA
  2. 2Johns Hopkins University, BALTIMORE, MD, USA
  3. 3Icahn School of Medicine at Mount Sinai, New York, NY, USA
  4. 4Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA


Background Prostate cancer is the second leading cause of cancer related death in men in the United States, mainly due to disease progression to metastatic castration-resistant prostate cancer (mCRPC). Although immunological treatment with the FDA-approved vaccine sipuleucel-T extends survival for 2–4 months by targeting the prostate-restricted antigen PAP, the identification of more immunogenic tumor-associated antigens (TAAs) continues to be an unmet need.

Methods We evaluated the differential expression profile of the subset of epithelial cells reported to give rise to CRPC from mice following an androgen deprivation/repletion cycle. The expression levels of a set of androgen-responsive genes was further evaluated in prostate, brain, colon, liver, lung, and skin normal tissues from murine and human databases. The expression of a novel prostate-restricted TAA was then analyzed in primary tumors across all human cancer types in The Cancer Genome Atlas (TCGA). Finally, the immunogenicity of this novel prostate-restricted TAA was evaluated in vitro by autologous co-culture assays with cells from healthy donors and in vivo by antibody profiling (PhIP-Seq) in the sera of a cohort of prostate cancer patients treated with AR blockade alone or in combination with the cell-based vaccine GVAX.

Results Here, we discovered a set of androgen-responsive genes exclusively expressed by the putative cell-of-origin for prostate cancer. We confirmed prostate-restricted enrichment of these androgen-responsive genes in normal tissues from murine and human databases. Among these prostate-restricted genes, we identified PAP, PSA, and a novel non-mutated TAA. This novel TAA was confirmed to be expressed in prostate cancer. Furthermore, its expression was associated with survival in patients with primary prostate cancer. Interestingly, we found that pro-inflammatory activated TBET+ EM CD8 and CD4 T cells were expanded by moDCs pulsed with our novel TAA to a greater extent than moDCs pulsed with either PAP or PSA were used. An IgG antibody response to this novel TAA was detected in 30% of vaccinated patients, while fewer than 8% of vaccinated patients developed antibody responses to PSA or PSMA.

Conclusions Taken together, these results suggest we have found a novel immunogenic prostate-restricted TAA that represents a promising therapeutic target for treating mCRPC.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.